COVID vaccine Covovax’s inclusion in the vaccination programme for the 12-17 years age group has been recommended by the COVID-19 Working Group, official sources said yesterday.
The Central Drugs Standard Control Organisation’s (CDSCO) Subject Expert Committee (SEC) had approved the Serum Institute of India’s Covovax for restricted use in emergency situations in adults on 28th December. On 9th March, it recommended granting the Emergency Use Authorisation (EUA) for Covovax for kids in the 12-17 age group.
The COVID-19 Working Group has now recommended to the National Technical Advisory Group on Immunisation’s (NTAGI) Standing Technical Sub Committee that Covovax be included in the national vaccination programme for those aged 12 years and above, sources said.
As per the source, a meeting of the COVID-19 Working Group was held on 1st April to review the data. Covovax is manufactured by technology transfer from Novavax.
Edits by EP News Bureau